Athira Pharma, Inc. (NASDAQ:LONA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Athira Pharma, Inc. (NASDAQ:LONA) has earned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $16.00.

LONA has been the topic of a number of recent research reports. Citizens Jmp raised shares of Athira Pharma from a “market perform” rating to an “outperform” rating and set a $18.00 target price on the stock in a research report on Thursday, July 30th. Wall Street Zen raised shares of Athira Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research note on Friday, August 7th. Finally, Piper Sandler started coverage on shares of Athira Pharma in a report on Wednesday, May 27th. They issued an “overweight” rating and a $20.00 price objective on the stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LONA. Seven Fleet Capital Management LP purchased a new position in Athira Pharma during the fourth quarter valued at $969,000. Perceptive Advisors LLC grew its stake in shares of Athira Pharma by 244.1% in the fourth quarter. Perceptive Advisors LLC now owns 1,859,322 shares of the company’s stock worth $14,075,000 after acquiring an additional 1,319,026 shares during the last quarter. Millennium Management LLC bought a new position in shares of Athira Pharma during the fourth quarter valued at $2,456,000. Commodore Capital LP bought a new position in shares of Athira Pharma during the fourth quarter valued at $3,515,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Athira Pharma in the 4th quarter worth about $2,891,000. Institutional investors own 57.12% of the company’s stock.

Athira Pharma Stock Performance

Athira Pharma stock opened at $7.98 on Monday. Athira Pharma has a fifty-two week low of $3.52 and a fifty-two week high of $14.21. The stock’s 50 day simple moving average is $8.26 and its two-hundred day simple moving average is $8.19. The stock has a market cap of $74.93 million, a price-to-earnings ratio of -1.53 and a beta of 2.04.

Athira Pharma (NASDAQ:LONA) last released its earnings results on Friday, August 14th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). On average, analysts predict that Athira Pharma will post -3.12 earnings per share for the current year.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.